Can SSRIs (including Lexapro) reduce the risk of long COVID?

What the New Studies Show About SSRIs and Long COVID

Over the past two years, long COVID has shifted from an emergency-era mystery to one of the most actively investigated chronic conditions in medicine. Among the more unexpected findings has been a series of large observational studies suggesting that SSRIs, including escitalopram (Lexapro), may be associated with a modestly lower risk of developing long COVID. These signals are far from conclusive, but they have been robust enough to capture the attention of infectious disease researchers, psychiatrists, and epidemiologists alike.

One of the strongest analyses comes from BMC Medicine (2024), which evaluated electronic health records from more than 300,000 adults with depression who later contracted and recovered from COVID-19. The study compared long-COVID diagnosis rates between those who were already taking an SSRI before infection and those who were not. After adjusting for age, comorbidities, socioeconomic factors, baseline mental health, and severity of COVID-19 illness, the researchers found that SSRI users had an 8-10% lower relative risk of receiving a long-COVID diagnosis. The effect size is small but statistically meaningful, especially given the enormous sample and careful adjustment for confounders.

A second analysis looked not only at SSRIs as a class but at individual antidepressant medications, including escitalopram. Here, the pattern shifted slightly: while escitalopram showed the same general protective direction of effect, the confidence intervals crossed 1. In plain terms, this means the data were too imprecise to confirm that escitalopram itself reduces long-COVID risk. The overall trend remains promising, but no single drug, Lexapro included, can yet be labeled as definitively protective.

Then, in 2025, another major study published in the International Journal of Infectious Diseases compared people taking SSRIs with those prescribed non-SSRI antidepressants, such as bupropion, mirtazapine, or tricyclics. The results again showed lower long-COVID rates among SSRI users, suggesting that there may be something pharmacologically meaningful about the SSRI class itself rather than depression treatment in general. The replication of this association across data sets is notable, but still observational. This point is essential: none of these studies are randomized controlled trials. They rely on electronic health records, not controlled drug assignments. Even with sophisticated statistical adjustments, such studies cannot prove that SSRIs cause lower long-COVID risk. People who take antidepressants differ from those who do not in many ways (health-seeking behavior, comorbidity profiles, frequency of healthcare visits, adherence patterns), and these differences may influence the results.

Still, the consistency of the findings has raised an important question: could SSRIs genuinely influence the biological pathways involved in long COVID?

Why Scientists Think SSRIs Might Affect Long COVID Biology

The notion that antidepressants might influence long COVID risk may seem counterintuitive at first. SSRIs were designed to treat depression and anxiety, not viral complications. Yet as long-COVID research has expanded, a surprising overlap has emerged between the drug’s biological effects and several pathways thought to contribute to persistent post-COVID symptoms. None of these mechanisms prove a therapeutic benefit, but they provide a plausible scientific rationale that helps explain why researchers are paying attention.

One of the earliest hypotheses centers on serotonin signaling, which plays a role not only in mood but also in immune modulation, autonomic function, sleep regulation, and gastrointestinal physiology – all systems commonly disrupted in long COVID. Emerging studies suggest that SARS-CoV-2 infection may alter serotonin metabolism through inflammation of the gut and changes in platelet activation.

Long-COVID patients, in some analyses, show reduced circulating serotonin levels, potentially contributing to fatigue, dysautonomia, and cognitive symptoms. Because SSRIs increase serotonin availability by blocking its reuptake, some scientists have speculated that they could partially normalize serotonin-related pathways disrupted by the infection. Another line of interest comes from the anti-inflammatory properties of SSRIs. Although antidepressants are not anti-inflammatory drugs in the traditional sense, multiple laboratory and clinical studies have demonstrated their ability to dampen the production of certain pro-inflammatory cytokines. Chronic low-grade inflammation is a leading hypothesis for long COVID, with elevated cytokine signatures observed months after acute illness. By reducing inflammatory signaling, SSRIs might theoretically help limit some of the immunological cascades implicated in long-term symptoms.

A third mechanism that has drawn attention involves the sigma-1 (?1) receptor, a chaperone protein located at the junction of the endoplasmic reticulum and mitochondria. Several SSRIs, notably fluvoxamine, but also escitalopram to a lesser extent, act as ?1-receptor agonists. Activation of this receptor may modulate cellular stress responses, reduce excessive cytokine release, and stabilize mitochondrial function. Early in the pandemic, ?1-receptor signaling became a candidate mechanism for reducing severe COVID complications, though clinical results were mixed. Still, the receptor’s known role in immune and metabolic regulation has kept it in the conversation as researchers investigate post-acute syndromes.

Finally, there is the broader idea of neuroimmune interaction, which links stress, infection, inflammation, and neural circuits. SSRIs have been shown in some settings to alter microglial activity, promote neuroplasticity, and influence pathways associated with both mood and cognition. Because long COVID often involves brain fog, executive dysfunction, anxiety, and impaired stress regulation, any drug affecting neuroimmune balance becomes theoretically relevant, even if its clinical benefit remains unproven.

None of these biological explanations confirm that SSRIs reduce long COVID risk. They are hypotheses, not established mechanisms. But they help contextualize why multiple independent observational studies have found similar patterns, and why SSRIs have emerged as intriguing candidates for future clinical trials. In a field where few treatments have demonstrated clear effectiveness, the convergence of epidemiological signals and plausible biological pathways is enough to justify deeper investigation.

Why You Shouldn’t Take Lexapro “Just in Case” to Prevent Long COVID

With several large studies showing modest associations between SSRI use and reduced long-COVID diagnoses, it is understandable that some people might wonder whether starting a medication like Lexapro could offer protection. But this is precisely where the science must be interpreted with caution. None of the existing evidence supports taking an SSRI proactively to prevent long COVID, and doing so may expose people to risks that far outweigh any theoretical benefit.

The most important point is that the studies identifying reduced long-COVID rates in SSRI users examined people who were already taking these medications for clinical reasons, typically depression or anxiety. These individuals were not taking SSRIs to influence COVID outcomes; they were receiving appropriate psychiatric treatment. Their level of medical supervision, frequency of healthcare interactions, and medication adherence patterns differ significantly from those of people who might consider starting Lexapro solely as a protective measure. In observational epidemiology, these differences matter. They introduce biases that can create associations even when no causal effect exists.

SSRIs also come with side effects that may be mild for some patients but troublesome for others. Escitalopram can cause nausea, sexual dysfunction, insomnia or sedation, gastrointestinal changes, headaches, and agitation, especially during the first weeks of treatment. (Lexapro Side Effects Guide ) These effects can meaningfully affect quality of life and often require dosage adjustments, careful monitoring, or even switching to a different antidepressant. Taking Lexapro without a psychiatric indication exposes someone to these burdens without a proven clinical benefit. There is also the issue of withdrawal, or discontinuation symptoms, which can include dizziness, “brain zaps,” irritability, and flu-like sensations. These symptoms are not dangerous but can be uncomfortable and may last several weeks, especially if the medication is stopped abruptly. Starting an SSRI for non-psychiatric reasons creates the possibility of unnecessary withdrawal once the person decides to stop.

Another concern is diagnostic confusion. SSRIs influence mood, anxiety, sleep, cognitive processing, and emotional responsiveness. Beginning one “just in case” could mask early symptoms of depression or anxiety, complicating later diagnosis and treatment. It might also delay the identification of long COVID itself. If a patient develops persistent fatigue, cognitive changes, or autonomic symptoms after a SARS-CoV-2 infection, clinicians need to evaluate these signs without the confounding effects of a newly initiated psychiatric medication.

There is also the broader ethical and medical principle of indication-based prescribing. SSRIs are powerful central nervous system medications that should not be started solely because an observational signal suggests they might help with a post-viral syndrome. The appropriate sequence is the opposite: first gather rigorous data through randomized controlled trials, then consider clinical guidelines if benefits clearly outweigh risks. At the moment, such trial evidence does not exist for escitalopram or any other SSRI in long COVID prevention.

Finally, there is a misconception that “a small benefit is better than nothing.” In pharmacology, this is not always true. A population-level association showing an 8-10% reduction in long-COVID diagnoses does not translate to a meaningful benefit for an individual patient, especially when weighed against the real-world costs, side effects, follow-up needs, and potential withdrawal symptoms of unnecessary SSRI use. The studies do not support self-medication, and clinicians strongly advise against it.

In short, while SSRIs are essential medications for many people, starting Lexapro solely to reduce the risk of long COVID is not supported by current evidence and is medically unadvised. The signals are scientifically interesting, but they are not instructions for the public.

What Clinicians and Researchers Currently Recommend

Taken together, the new data paint a picture that is promising but incomplete. On one hand, multiple large observational cohorts now suggest that SSRIs are associated with a modestly lower risk of long COVID in people with depression who become infected with SARS-CoV-2. In BMC Medicine’s N3C analysis, SSRI users had an adjusted relative risk of about 0.9 for long COVID compared with non-users. In the Infection cohort based on TriNetX data, SSRI users showed hazard ratios between 0.57 and 0.59 compared with patients taking non-SSRI antidepressants. At the same time, clinical experience is beginning to accumulate in patients who already have long COVID. A 2023 open-label study in Scientific Reports followed 95 post-COVID syndrome patients treated with different SSRIs and reported substantial improvement in well-being, with reductions in brain fog, sensory overload, fatigue, and dysautonomia in most participants. These are not randomized trials, but they are consistent with the idea that SSRIs may modulate some of the neuroimmune mechanisms that sustain persistent symptoms.

Because of this convergence of epidemiological signals and mechanistic plausibility, narrative reviews in 2024-2025 have started to cautiously describe SSRIs as “candidates” for long-COVID prevention or treatment, not established therapies. A clinical commentary in Prim Care Companion CNS Disorders summarizes the field as “growing evidence” rather than proof, stressing that antidepressants should still be prescribed primarily for psychiatric indications until randomized trials clarify their role in long COVID.PubMed

For clinicians, the current practical message is relatively conservative. If a patient already has a clear indication for an SSRI, such as major depression or significant anxiety, and also has risk factors for long COVID, these data may provide reassurance that continuing or initiating SSRI treatment is unlikely to worsen COVID outcomes and may offer a small protective effect. For patients who already live with long COVID and co-occurring depression, SSRIs might reasonably be considered part of an integrated treatment plan, with the understanding that any improvement in physical symptoms is still exploratory rather than guaranteed.

Guidelines have not endorsed SSRIs as a standard long-COVID therapy or prophylaxis. Expert groups emphasize that only randomized, controlled trials can determine whether the observed associations are causal, what doses and durations are optimal, and which subgroups might benefit. Until those trials report, the role of SSRIs in long COVID should be viewed as an emerging research frontier: important, intriguing, but not yet ready for routine use outside the contexts just described.

Conclusion

Current evidence suggests that people already taking SSRIs, possibly including escitalopram, have a slightly lower recorded risk of long COVID and that some long-COVID patients report symptom relief on these medications. But these findings come from observational cohorts and open-label studies, not definitive trials. The biological hypotheses around serotonin, inflammation, and ?1-receptor signaling are compelling, yet still theoretical. For now, SSRIs should not be started “just in case” to prevent long COVID; they remain psychiatric drugs whose use must be based on clear clinical indications and guided by a treating physician, while the research community works toward the randomized trials needed to turn signals into solid recommendations.

References

1. Butzin-Dozier, Z., Ji, Y., Deshpande, S., Hurwitz, E., Anzalone, A. J., Coyle, J., Shi, J., Mertens, A., van der Laan, M. J., Colford, J. M., Patel, R. C., Hubbard, A. E., & National COVID Cohort Collaborative (N3C) Consortium. (2024). SSRI use during acute COVID-19 and risk of long COVID among patients with depression.BMC Medicine, 22, 445. https://doi.org/10.1186/s12916-024-03655-x
2. Gao, Z., Tabernacki, T., Davis, P. B., Kaelber, D. C., & Xu, R. (2025). Associations of selective serotonin reuptake inhibitors and long COVID risk in patients with depression: A retrospective cohort study. Infection. Advance online publication. https://doi.org/10.1007/s15010-025-02648-z
3. Rivas-Vazquez, R. A., Carrazana, E. J., Rivas-Vazquez, E. V., & Quintana, A. (2024). Growing evidence for potential use of antidepressants for long COVID. Primary Care Companion for CNS Disorders, 26(3), 23lr03690. https://doi.org/10.4088/PCC.23lr03690/li>
4. Rus, C. P., de Vries, B. E. K., de Vries, I. E. J., Nutma, I., & Kooij, J. J. S. (2023). Treatment of 95 post-COVID patients with SSRIs. Scientific Reports, 13, 18599. https://doi.org/10.1038/s41598-023-45072-9